Results The study showed that semaglutide treatment for type 2 diabetes and obesity was associated with a lower risk of tobacco use-related health encounters as compared to other type 2 diabetes medications, especially in the first month of prescription
Proven Cardiovascular Benefits Reduced major adverse cardiovascular events (MACE) Reduced heart failure risk Anti-atherosclerotic effects Blood pressure reduction Weight-mediated cardiometabolic improvement Semaglutide and liraglutide especially demonstrated major cardiovascular outcome benefits
A "GLP-1 patch" claims to do the same for GLP-1 activity, offering a no-injection alternative to prescription GLP-1 receptor agonists like semaglutide
Fill most of your plate with non-starchy vegetables
3B, 4B, and Table 3)
Two defense-related genes, encoding a GST and a cytochrome P450, were regulated downstream of WRKY45, but were not regulated by NH1, suggesting independence of the WRKY45 and NH1 pathways (Shimono et al., 2007)
